🌟 Exciting news from Cellmover 🌟 We are thrilled to announce that Cellmover has been awarded funding from the prestigious #Eurostars program in collaboration with our partner, RED GLEAD DISCOVERY, in Sweden. This support propels us forward as we advance our lead candidate, CM101—a nanobody-based therapy designed to fight lung cancer. It also reinforces our mission to innovate and develop novel biologics that can transform patient care. With this milestone, we are ready to elevate our research and make significant progress during the next years. The future of immunotherapy is bright, and we are excited to contribute to this transformative journey. Norges forskningsråd ShareLab The Life Science Cluster MedWatch Norge Innovasjon Norge forskning.no Forskningsparken - Oslo Science Park
Cellmover
Bioteknologisk forskning
Vestre Aker, Oslo 272 følgere
Cellmover is a pre-clinical stage company focusing on innovative strategies to enhance immune cell activation
Om oss
Cellmover is a pre-clinical stage immunotherapy company focusing on the development of novel strategies to enhance immune cell activation. Our primary focus includes delivery of therapeutic modules into immune cells and enhancing lymphocyte homing to tumors.
- Nettsted
-
https://www.cellmover.com
Ekstern lenke til Cellmover
- Bransje
- Bioteknologisk forskning
- Bedriftsstørrelse
- 2–10 ansatte
- Hovedkontor
- Vestre Aker, Oslo
- Type
- Privateid selskap
- Grunnlagt
- 2015
Beliggenheter
-
Primær
Melkeveien 39
Vestre Aker, Oslo 0779, NO
Ansatte i Cellmover
Oppdateringer
-
First training camp ✅ A big thank you to Life Science Academy for Startups and HØIBERG - European Patent Attorneys for an insightful workshop on refining our IP strategy! 🚀 For a small startup, understanding and managing intellectual assets - like patents, trade secrets and know-how - is vital for success at every stage of development. The session highlighted the strategic importance of these tools in driving innovation and protecting our future growth. We’re already excited for the next training camp and proud to be part of this academy for startups program 🙌🏼 The Life Science Cluster Norges forskningsråd Innovasjon Norge ShareLab Women in Life Science Norway (WiLD Norway)
-
We had the pleasure of attending the annual InLifeScience conference yesterday, organized by The Life Science Cluster and Tekna. As a proud member of TLSC, we were invited to showcase our solution in the networking area🙌🏼 The event’s panel discussions were especially insightful, emphasizing the importance of advancing women's health, embracing AI as the future of life sciences, fostering a pro-innovation mindset and proving that scientific excellence goes hand-in-hand with societal impact👏🏼 Forskningsparken - Oslo Science Park Norges forskningsråd Oslo Science City
-
Cellmover was present at the launch of Women in Life Science Norway #WilDNorway this afternoon, by initiative from Chelsea Ranger! We are honored to be members of this network of successful women who have made their careers in life science, and ready to motivate other women to take leadership positions in life science. There is still a gap that we need to fill, and there is no lack of highly competent women in Norway!!! Cellmover has a female management with Miriam Aarsund Larsen as CSO and Marit Inngjerdingen as CEO, and we can only recommend to take the leap into starting a company! ShareLab Forskningsparken - Oslo Science Park Norges forskningsråd
-
Yesterday, CEO, Marit Inngjerdingen and CSO, Miriam Aarsund Larsen attended Dehns event for an insightful panel discussion and AW at Forskningsparken - Oslo Science Park highlighting the importance of intellectual assets in start-ups🚀 It was great to connect with familiar and new faces and discussing the value of innovation in the context of growth, patents and investments👏🏼 Völur SINTEF Vilje Bionics Startuplab
-
Our CSO Miriam Aarsund Larsen gave a company pitch this morning at the First Friday Coffee seminar series at Forskningsparken - Oslo Science Park. Great opportunity to connect with other members and get to know new companies in the park🙌🏼 ShareLab Oslo Science City
-
We are super excited to move into ShareLab and continue developing our novel immunotherapies in Sharelab’s vibrant lab incubator🚀 Forskningsparken - Oslo Science Park forskning.no Norges forskningsråd
CELLMOVER JOINS SHARELAB We are excited to announce that Cellmover, a pioneering pre-clinical stage immunotherapy company, has joined ShareLab’s incubator community at Oslo Science Park. Cellmover's plan is to revolutionize cancer treatment through advanced immunotherapy techniques that optimize immune system tools to fight various cancers. Their team is powered by the expertise of Professor Marit Inngjerdingen, CEO, and Dr. Miriam Aarsund Larsen, CSO. Serial entrepreneur Eirik Næss-Ulseth chairs the board and brings vast experience in developing technology-based companies. Said Marit Inngjerdingen, CEO of Cellmover: “We are excited to become a part of the ShareLab family. This marks a milestone for our company. Our ShareLab membership enables us to accelerate our R&D, open new opportunities for collaboration, and strengthen our mission to develop cancer immunotherapies.” Marius Øgaard, co-founder of ShareLab, commented: “Cellmover’s management team is highly competent and possesses rock-solid experience in both science and business. They also have cutting-edge ideas about curing cancer. As a team launching a new deep tech startup, they’re ‘the Right Stuff’, and we are super happy to have them on board at ShareLab!” Marit Inngjerdingen Eirik Næss-Ulseth Miriam Aarsund Larsen Esben A. Nilssen Flore Kersten Samrawit Michael Emilie Steinbakk Ulriksen Nora Emini
-
🔬 Join the Cellmover Team! Are you passionate about advancing innovative therapies? We're hiring! Apply now to be part of our journey developing novel cancer therapeutics. Deadline: 30.04 #Nanotechnology #Biotech #Innovation #CancerReseach
-
Vi takker for støtten fra Norges forskningsråd som har gjort det mulig for oss å utvikle nye idéer for fremtidens kreftbehandling!
Visste du at det i Norge er over 316 000 personer som har kreft eller har hatt kreft? Og at før fylte 80 år har rundt 4 av 10 nordmenn fått minst én kreftdiagnose? I dag markeres FNs internasjonale kreftdag. 💙 Fordi det forskes på kreft, overlever 3 av 4 som får kreft i Norge. Det er dobbelt så mange som for 50 år siden. Vi i Forskningsrådet har i perioden 2017-2022 gitt 1,5 milliarder i finansiering til norske aktører som forsker på kreft. Noen av disse er bedriftene PubGene AS, Cellmover og EXACT Therapeutics. Hør dem fortelle med egne ord hvilken nytteverdi deres forskning har for norske kreftpasienter. #verdenskreftdag #idekraftverdentrenger #kreftforskning Kreftforeningen Ole Alexander Opdalshei Marit Inngjerdingen Miriam Aarsund Larsen Morten Smedsrud Wigen Tor-Kristian Jenssen